Treatment of ECL cell carcinoids with octreotide LAR
The DOI matches its Crossref record.
Abstract
BACKGROUND: Patients with chronic atrophic gastritis (CAG) and hypergastrinaemia are at risk of developing hyperplasia of the enterochromaffin-like (ECL) cells and ECL-cell-derived tumours. The effect of the somatostatin analogue octreotide on ECL cell carcinoids is examined. METHODS: Five patients with hypergastrinaemia and ECL cell carcinoids were enrolled in a 1-year study of octreotide LAR (long-acting release) 20 mg given at monthly intervals. Biopsies from tumours and from flat oxyntic mucosa were done at the start and 3, 6 and 12 months thereafter. Sections were stained with haematoxylin-erythrosin, immunostained with chromogranin A (CgA) and doublestained with CgA and Ki-67. Serum gastrin and CgA were measured. RESULTS: The number of visible tumours was reduced by more than 50 %. Sections from both tumours and flat mucosa showed a reduced number of CgA immunoreactive cells. Mean serum gastrin decreased from 421 to 186 pM (normal <40 pM); P > 0.05, and serum CgA from 73 to 25 ng/ml (normal < 30 ng/ml); P < 0.001. CONCLUSIONS: During treatment the patients were still markedly hypergastrinaemic, whereas the serum CgA showed normalization. A diminished tumour load and reduced ECL cell density were found, indicating an antiproliferative effect of octreotide directly on the ECL cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., et al. (2012) · Neuroendocrinology · doi:10.1159/000329043 · Cited by 132
Long-term results of endoscopic resection for type I gastric neuroendocrine tumors
Uygun, A., Kadayifci, A., Polat, Z., Yilmaz, K., Gunal, A., Demir, H., & Bagci, S. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23477 · Cited by 62
The Enterochromaffin-like [ECL] Cell—Central in Gastric Physiology and Pathology
Waldum, H. L., Sørdal, Ø. F., & Mjønes, P. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102444 · Cited by 45
Self-citation
Metadata
- Authors
- Fykse, V., Sandvik, A. K., Qvigstad, G., Falkmer, S. E., Syversen, U., & Waldum, H. L.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2004-01
- Volume
- 39
- Issue
- 7
- Pages
- 621-628
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2080419869
- Cited by
- 76
- References
- 0
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of ECL cell carcinoids with octreotide LAR. https://app.cochat.ai/papers/10.1080/00365520410005225
- The paper
- Fykse, V., Sandvik, A. K., Qvigstad, G., Falkmer, S. E., Syversen, U., & Waldum, H. L. (2004). Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365520410005225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.